Trial reportJournal of immunotherapy (Hagerstown, Md. : 1997)
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
Trial report in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 222 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of Subcutaneous "CYT 99 007" (Interleukin-7) in Conjunction With Peptide Immunization in Patients With Metastatic Melanoma
A Phase I Study of CYT107 (Recombinant Glycosylated Human IL-7) in Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant
A Randomised, Multicentric, Phase 2a Study Evaluating the Impact of an Immunotherapy by IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients
Who cites it
222 citing papers in PubMed.
- Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.JCI insight · 2018Trial
- Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- Trial
- Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.The Journal of clinical investigation · 2009Trial
- IL7R mRNA therapy enhances antitumor T cell immunity and suppresses tumor growth in preclinical tumor models.Journal for immunotherapy of cancer · 2026Article
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- Expansion and mobilization of virus-specific stem-like CD8 T cells in chronic viral infection after treatment with a long-acting IL-7, NT-I7.Cell reports · 2026Article
- Biomarkers in QuantiFERON Supernatants May Help Distinguish Latent Tuberculosis Infection From Active Tuberculosis: Preliminary Report.Mediators of inflammation · 2026Article
- Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer.Life medicine · 2025Article
- GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8British journal of cancer · 2025Article
- Immunosenescence: signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Burning Down the House: Thymic Repair and Regeneration After Acute Damage.Immunological reviews · 2025Review
- Evaluation of Cytokine Profile in Canine Malignant Oral Melanoma.Veterinary sciences · 2025Article
- Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.Molecular therapy. Oncology · 2025Article
- Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.Journal for immunotherapy of cancer · 2025Article
- Endogenous IL-7 Variation in Relation to Lymphocyte Subtypes in Septic Patients.Medicina (Kaunas, Lithuania) · 2025Observational
- Tumor cells ectopically expressing the membrane-bound form of IL-7 develop an antitumor immune response efficiently in a colon carcinoma model.Molecules and cells · 2025Article
- Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer.Drug design, development and therapy · 2025Article
- IL-7: a potential next-generation adjuvant for immune cell therapies.Frontiers in immunology · 2025Review
162 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Lymphopenia is a serious consequence of HIV infection and the administration of cancer chemotherapeutic agents. Although growth factors can be administered to patients to increase circulating neutrophils, there is no effective method to stimulate CD8+ lymphocyte production in humans, in vivo. This report is the first to describe the administration of recombinant interleukin-7 to humans and demonstrates the ability of this cytokine to mediate selective increases in CD4+ and CD8+ lymphocytes along with a decrease in the percentage of CD4+ T-regulatory cells. These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.